Volume 26, Number 3—March 2020
Research
Human Immune Responses to Melioidosis and Cross-Reactivity to Low-Virulence Burkholderia Species, Thailand1
Table 1
Cohort | No. (%) samples by assay |
||
---|---|---|---|
IHA or ELISA | IFN-γ ELISpot | WBA | |
Melioidosis, n = 99 | 73 (74) | 82 (83) | 13 (13) |
Healthy household contacts, n = 96 | 35 (36) | 93 (97) | 8 (8) |
Diabetes control, n = 98 | 54 (55) | 95 (97) | NA |
Other gram-negative bacterial infections, n = 48 | 10 (20) | 42 (88) | NA |
*IFN-γ ELISpot, interferon-γ enzyme-linked immunospot assay; IHA, indirect hemagglutination assay; NA, not available; WBA, whole-blood stimulation assay.
1Preliminary results from this study were presented at the European Melioidosis Congress, March 19–21, 2018, Oxford, UK.
Page created: February 19, 2020
Page updated: February 19, 2020
Page reviewed: February 19, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.